Claire Provost

Dr. Claire Provost

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
ACAlex Cazes
Alex Cazes
LLLucille Lopez-Delisle
Lucille Lopez-Delisle
KTKonstantina Tsarovina
Konstantina Tsarovina
CPCécile Pierre-Eugène
Cécile Pierre-Eugène
KPKatleen De Preter
Katleen De Preter
IJIsabelle Janoueix-Lerosey
Isabelle Janoueix-Lerosey
Activating mutations of the ALK (Anaplastic lymphoma Kinase) gene have been identified in sporadic and familial cases of neuroblastoma, a cancer of early childhood arising from the sympathetic nervous system (SNS). To decipher ALK function in neuroblastoma predisposition and oncogenesis, we have characterized knock-in (KI) mice bearing the two most frequent mutations observed in neuroblastoma patients. A dramatic enlargement of sympathetic ganglia is observed in Alk F1178L mice from embryonic to adult stages associated with an increased proliferation of sympathetic neuroblasts from E14.5 to birth. In a MYCN transgenic context, the F1178L mutation displays a higher oncogenic potential than the R1279Q mutation as evident from a shorter latency of tumor onset. We show that tumors expressing the R1279Q mutation are sensitive to ALK inhibition upon crizotinib treatment. Furthermore, our data provide evidence that activated ALK triggers RET upregulation in mouse sympathetic ganglia at birth as well as in murine and human neuroblastoma. Using vandetanib, we show that RET inhibition strongly impairs tumor growth in vivo in both MYCN/KI Alk R1279Q and MYCN/KI Alk F1178L mice. Altogether, our findings demonstrate the critical role of activated ALK in SNS development and pathogenesis and identify RET as a therapeutic target in ALK mutated neuroblastoma.

7 March 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
AGAnne-Claire Guénantin
Anne-Claire Guénantin
NBNolwenn Briand
Nolwenn Briand
ECEmilie Capel
Emilie Capel
FDFlorent Dumont
Florent Dumont
RMRomain Morichon
Romain Morichon
CVCorinne Vigouroux
Corinne Vigouroux
Activation of thermogenic beige adipocytes has recently emerged as a promising therapeutic target in obesity and diabetes. Relevant human models for beige adipocyte differentiation are essential to implement such therapeutic strategies. We report a straightforward and efficient protocol to generate functional human beige adipocytes from human induced pluripotent stem cells (hiPSCs). Without overexpression of exogenous adipogenic genes, our method recapitulates an adipogenic developmental pathway through successive mesodermal and adipogenic progenitor stages. hiPSC-derived adipocytes are insulin sensitive and display beige-specific markers and functional properties, including upregulation of thermogenic genes, increased mitochondrial content, and increased oxygen consumption upon activation with cAMP analogs. Engraftment of hiPSC-derived adipocytes in mice produces well-organized and vascularized adipose tissue, capable of β-adrenergic–responsive glucose uptake. Our model of human beige adipocyte development provides a new and scalable tool for disease modeling and therapeutic screening.

12 January 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JMJérémy Malinge
Jérémy Malinge
BGBastien Géraudie
Bastien Géraudie
PSPaul Savel
Paul Savel
VNValérie Nataf
Valérie Nataf
APAurélie Prignon
Aurélie Prignon
CMChristine Ménager
Christine Ménager

23 April 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
APAurélie Prignon
Aurélie Prignon
CPClaire Provost
Claire Provost
FAFaisal Alshoukr
Faisal Alshoukr
DWDominique Wendum
Dominique Wendum
ACAnne Couvelard
Anne Couvelard
AGAnne Gruaz-Guyon
Anne Gruaz-Guyon

1 February 2015 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
APA. Prignon
A. Prignon
VNV. Nataf
V. Nataf
CPClaire Provost
Claire Provost
ACA. Cagnolini
A. Cagnolini
FMF. Montravers
F. Montravers
ANAd. Nunn
Ad. Nunn

1 May 2020 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
Jules Zhang-YinJules Zhang-Yin
Jules Zhang-Yin
CPClaire Provost
Claire Provost
GCGéraldine Cancel-Tassin
Géraldine Cancel-Tassin
TRTimofei Rusu
Timofei Rusu
MPMallaurie Penent
Mallaurie Penent
APAurélie Prignon
Aurélie Prignon